Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
Eiger announced ILIAD study results of peginterferon lambda in COVID-19 published in Lancet
On Feb. 8, 2021, Eiger BioPharmaceuticals announced that the final results from the Phase 2 ILIAD (Interferon Lambda…
NanoViricides’s antiviral drug candidate for treatment of COVID-19 infections well tolerated in animal safety studies
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
Repligen and Navigo Proteins announced the launch of affinity resin for the purification of COVID-19 vaccines
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they had completed the development and initiated the…
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the FDA to a…
US COVID-19 infections nearly three times greater than reported, UTSW model estimated
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
ChAdOx1 nCov-19 provided minimal protection against mild-moderate COVID-19 infection from B1351 coronavirus variant in young South African adults
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
CureVac and UK Government announced collaboration on development of vaccines against SARS-CoV-2 variants
On Feb. 5, 2021, CureVac announced that it had entered a collaboration with the UK Government to develop…
The Wellcome Sanger Institute announced sequencing 136,383 Coronavirus genomes in the UK
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
FDA approved new treatment for adults with relapsed or refractory large-B-Cell lymphoma
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
Oxford University vaccine effective against major B117 ﾑKentﾒ coronavirus strain circulating in the UK
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxfordﾒs…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
The US Department of Defense announced use of masks and other public health measures
On Feb. 4, 2021, the U.S. Department of Defense Secretary of Defense directed all individuals on military installations…
Johnson & Johnson announced submission of application to FDA for EUA of its single-shot COVID-19 vaccine candidate
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
XPhyto announced psychedelic pharmaceutical production agreement
On Feb. 3, 2021, XPhyto announced an agreement with Applied Pharmaceutical Innovation for the synthesis of pharmaceutical grade…
Vaxart announced positive preliminary data from phase 1 clinical trial evaluating oral COVID-19 tablet vaccine candidate
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
Dynavax and Serum Institute announced first participant dosed in trial evaluating Tdap vaccine adjuvanted with CpG 1018
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
Humanigen and Avid Bioservices entered Into cGMP manufacturing agreement for COVID-19 therapeutic
On Feb. 3, 2021, Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement…
BD announced assay for identification of COVID-19 patients at increased risks of intubation available in Europe
On Feb. 3, 2021, BD (Becton, Dickinson) announced the CE mark of BD Multitestﾙ 6-Color TBNK Reagent with…
Bristol Myers and Rockefeller University announced license agreement for SARS-CoV-2 meutralizing mAb combination
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
GSK and CureVac announced JV to develop next generation mRNA COVID-19 vaccines
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new ﾀ150m collaboration, building on their existing relationship, to…
SARS-CoV-2 spike protein licensed by Oragenics from the NIH demonstrated protective immunity in mice
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
VBI Vaccines announced FDA Acceptance of BLA filing for VBIﾒs 3-antigen prophylactic hepatitis B vaccine
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
Roche announced launch of SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
On Feb. 1, 2021, Roche announced it had obtained the CE mark for its new SARS-CoV-2 Rapid Antigen…
NIH study showed hyaluronan effective in treating chronic lung disease
On Feb. 1, 2021, researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented…
Clover and Dynavax announced planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
Dynavax and CEPI announced $99 million in funding for CpG 1018 adjuvant manufacturing
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
Dynavax announced exercise of option to reserve additional CpG 1018 to produce 40 million doses of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option…